Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00130793
First received: August 11, 2005
Last updated: January 14, 2015
Last verified: January 2015
Results First Received: May 11, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Bio-equivalence Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Prevention
Condition: Herpes Zoster
Interventions: Biological: Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation
Biological: Comparator: zoster vaccine live (Oka/Merck) frozen formulation

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Patients were recruited at 14 sites in the United States.

First patient randomized: 08Aug2005; Last patient last visit: 28Nov2005


Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
ZOSTAVAX™ With PGSU ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
ZOSTAVAX™ With PGS ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection

Participant Flow:   Overall Study
    ZOSTAVAX™ With PGSU   ZOSTAVAX™ With PGS
STARTED   183   185 
Vaccinated   182 [1]   185 
COMPLETED   180 [2]   181 [3] 
NOT COMPLETED   3   4 
Lost to Follow-up                1                4 
Withdrew consent                2                0 
[1] One subject was allocated but not vaccinated.
[2] Subject received vaccine, completed blood draws, returned vaccination report card (VRC) at Week 4
[3] Subject received vaccine, completed blood draws, returned VRC at Week 4



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
ZOSTAVAX™ With PGSU ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
ZOSTAVAX™ With PGS ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection
Total Total of all reporting groups

Baseline Measures
   ZOSTAVAX™ With PGSU   ZOSTAVAX™ With PGS   Total 
Overall Participants Analyzed 
[Units: Participants]
 182   185   367 
Age 
[Units: Years]
Mean (Standard Deviation)
 63.4  (9.25)   63.2  (8.44)   63.35  (8.83) 
Gender 
[Units: Participants]
     
Female   97   106   203 
Male   85   79   164 
Race/Ethnicity 
[Units: Participants]
     
Asian   6   6   12 
Asiatic   1   4   5 
Black   19   15   34 
Hispanic American   30   34   64 
Indian   1   0   1 
Native American   1   0   1 
White   124   126   250 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination   [ Time Frame: 4 weeks ]

2.  Secondary:   Vaccine-Related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination   [ Time Frame: 4 weeks ]

3.  Other Pre-specified:   Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination   [ Time Frame: From prevaccination (baseline) to 4 weeks postvaccination ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com


Publications:

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00130793     History of Changes
Other Study ID Numbers: V211-010
2005_035
Study First Received: August 11, 2005
Results First Received: May 11, 2009
Last Updated: January 14, 2015
Health Authority: United States: Food and Drug Administration